Physician profile
Roy Burch
NPI 1073516225
$9,976.16
in general payments reported to CMS, 2019-2025
16 companies · $6,200 in 2025
The $6,200 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $37.25 · 2021: $57.63 · 2024: $3,262 · 2025: $6,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,400 · Food and Beverage: $62.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,400.00 |
| Food and Beverage | $62.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $9,400.00 | 2024-2025 | Bovine Collagen |
| Avanos Medical | $121.12 | 2019 | |
| Avion Pharmaceuticals | $65.94 | 2020-2021 | |
| Allergan, INC. | $63.91 | 2019 | |
| Daiichi Sankyo INC. | $47.29 | 2019 | |
| Abbvie INC. | $44.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.75 | 2019 | |
| Coopersurgical, INC. | $35.12 | 2020-2024 | Wallach Cryosurgical Equipment |
| Duchesnay USA Incorporated | $31.45 | 2019 | |
| Astellas Pharma US INC | $22.11 | 2024 | Veozah |
| Therapeuticsmd, INC. | $18.92 | 2019 | |
| Hologic Sales and Service, LLC | $18.50 | 2019 | |
| Merck Sharp & Dohme LLC | $18.03 | 2019 | |
| Organon LLC | $17.67 | 2024 | |
| Myovant Sciences INC. | $16.35 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.